Kurzporträt
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Bobby Gaspar
CEO | Chief Executive Officer | 60 | 01.01.15 |
Frank Thomas
PSD | President | 54 | 01.01.18 |
Leslie Meltzer
CTO | Chief Tech/Sci/R&D Officer | - | 01.06.18 |
Nicoletta Loggia
CTO | Chief Tech/Sci/R&D Officer | - | 09.09.21 |
Fulvio Mavilio
CTO | Chief Tech/Sci/R&D Officer | - | 01.01.22 |
Renee T. Leck
IRC | Investor Relations Contact | - | - |
Christopher York
SEC | Corporate Secretary | - | - |
Braden Parker
PRN | Corporate Officer/Principal | - | - |
John Cerio
HRO | Human Resources Officer | - | - |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Abdul Mullick
BRD | Director/Board Member | - | 24.01. |
Yasuo Fujii
BRD | Director/Board Member | - | 24.01. |
60 | - | ||
Director/Board Member | 62 | 24.01. |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 126 572 749 | 81 786 701 ( 64,62 %) | 0 | 64,62 % |
Unternehmenskontakt
Orchard Therapeutics Plc
245 Hammersmith Road 3rd Floor
W6 8PW, London
+44 20 3 808 8286
http://www.orchard-tx.comSektor
% 1. Jan. | Kap. | |
---|---|---|
+33,43 % | 690 Mrd. | |
+26,43 % | 546 Mrd. | |
-5,12 % | 358 Mrd. | |
+19,59 % | 323 Mrd. | |
+4,89 % | 287 Mrd. | |
+14,32 % | 235 Mrd. | |
+5,79 % | 199 Mrd. | |
-9,49 % | 195 Mrd. | |
+4,26 % | 161 Mrd. |